rs148921184
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM1PM2
The ENST00000274680.9(FARS2):c.1268G>A(p.Arg423Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00011 in 1,614,052 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R423W) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000274680.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FARS2 | NM_006567.5 | c.1268G>A | p.Arg423Gln | missense_variant | 7/7 | ENST00000274680.9 | NP_006558.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FARS2 | ENST00000274680.9 | c.1268G>A | p.Arg423Gln | missense_variant | 7/7 | 1 | NM_006567.5 | ENSP00000274680 | P1 | |
FARS2 | ENST00000324331.10 | c.1268G>A | p.Arg423Gln | missense_variant | 7/7 | 1 | ENSP00000316335 | P1 | ||
FARS2 | ENST00000648580.1 | c.1218-50367G>A | intron_variant, NMD_transcript_variant | ENSP00000497889 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152182Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000677 AC: 17AN: 251270Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135830
GnomAD4 exome AF: 0.000107 AC: 156AN: 1461752Hom.: 0 Cov.: 31 AF XY: 0.0000798 AC XY: 58AN XY: 727182
GnomAD4 genome AF: 0.000144 AC: 22AN: 152300Hom.: 0 Cov.: 33 AF XY: 0.000107 AC XY: 8AN XY: 74480
ClinVar
Submissions by phenotype
Combined oxidative phosphorylation defect type 14 Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 13, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 423 of the FARS2 protein (p.Arg423Gln). This variant is present in population databases (rs148921184, gnomAD 0.02%). This missense change has been observed in individual(s) with developmental delay, hypotonia, and speech delay (PMID: 28419689). ClinVar contains an entry for this variant (Variation ID: 214337). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FARS2 protein function. Experimental studies have shown that this missense change affects FARS2 function (PMID: 28419689). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine | Jun 13, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | May 01, 2019 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 28, 2023 | Variant summary: FARS2 c.1268G>A (p.Arg423Gln) results in a conservative amino acid change located in the Ferrodoxin-fold anticodon-binding domain (IPR005121) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.8e-05 in 251270 control chromosomes. c.1268G>A has been reported in the literature in individuals affected with developmental delay and hypotonia (Kartvelishvili_2017). This report does not provide unequivocal conclusions about association of the variant with FARS2-Related Disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 28419689). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 06, 2022 | The c.1268G>A (p.R423Q) alteration is located in exon 7 (coding exon 6) of the FARS2 gene. This alteration results from a G to A substitution at nucleotide position 1268, causing the arginine (R) at amino acid position 423 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 29, 2019 | Reported in an individual with developmental delay and hypotonia in published literature (Kartvelishvili et al., 2017); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as R387Q due to alternative nomenclature; This variant is associated with the following publications: (PMID: 28419689) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at